BACKGROUND: Congenital central hypoventilation syndrome (CCHS) is a rare condition that usually presents soon after birth and is potentially life-shortening if not treated. The defining abnormality is hypoventilation during sleep which requires life-long treatment with artificial ventilation. This syndrome may also be associated with generalised dysfunction of the autonomic nervous system and a sub-group with associated Hirschsprung's disease. The genetic basis of CCHS has been identified as mutations in the PHOX2B gene. METHODS: We present four families, three with autosomal dominant inheritance and familial clustering, and one with a de novo mutation resulting in CCHS. CONCLUSIONS: We demonstrate that nasal mask ventilation from birth can provide adequate treatment and improved quality of life for these children. Phenotypic variability in expression of disease is seen in families with the same mutations in PHOX2B gene. The psychosocial costs of the disease and the unrecognised 'morbidity barter' that is part of current management needs to be factored into in all stages of management from childhood to adolescence to adulthood.
BACKGROUND:Congenital central hypoventilation syndrome (CCHS) is a rare condition that usually presents soon after birth and is potentially life-shortening if not treated. The defining abnormality is hypoventilation during sleep which requires life-long treatment with artificial ventilation. This syndrome may also be associated with generalised dysfunction of the autonomic nervous system and a sub-group with associated Hirschsprung's disease. The genetic basis of CCHS has been identified as mutations in the PHOX2B gene. METHODS: We present four families, three with autosomal dominant inheritance and familial clustering, and one with a de novo mutation resulting in CCHS. CONCLUSIONS: We demonstrate that nasal mask ventilation from birth can provide adequate treatment and improved quality of life for these children. Phenotypic variability in expression of disease is seen in families with the same mutations in PHOX2B gene. The psychosocial costs of the disease and the unrecognised 'morbidity barter' that is part of current management needs to be factored into in all stages of management from childhood to adolescence to adulthood.
Authors: Emily S Todd; Seth M Weinberg; Elizabeth M Berry-Kravis; Jean M Silvestri; Anna S Kenny; Casey M Rand; Lili Zhou; Brion S Maher; Mary L Marazita; Debra E Weese-Mayer Journal: Pediatr Res Date: 2005-12-02 Impact factor: 3.756
Authors: Elizabeth M Berry-Kravis; Lili Zhou; Casey M Rand; Debra E Weese-Mayer Journal: Am J Respir Crit Care Med Date: 2006-08-03 Impact factor: 21.405
Authors: I Matera; T Bachetti; F Puppo; M Di Duca; F Morandi; G M Casiraghi; M R Cilio; R Hennekam; R Hofstra; J G Schöber; R Ravazzolo; G Ottonello; I Ceccherini Journal: J Med Genet Date: 2004-05 Impact factor: 6.318
Authors: Ajay S Kasi; Taryn J Jurgensen; Stephanie Yen; Sheila S Kun; Thomas G Keens; Iris A Perez Journal: J Clin Sleep Med Date: 2017-07-15 Impact factor: 4.062
Authors: Joana Magalhães; Núria Madureira; Rita Medeiros; Paula C Fernandes; Myriam Oufadem; Jeanne Amiel; M Helena Estêvão; M Guilhermina Reis Journal: Sleep Breath Date: 2014-05-04 Impact factor: 2.816
Authors: Ha Trang; Jean-François Brunet; Hermann Rohrer; Jorge Gallego; Jeanne Amiel; Tiziana Bachetti; Kenneth H Fischbeck; Thomas Similowski; Christian Straus; Isabella Ceccherini; Debra E Weese-Mayer; Matthias Frerick; Katarzyna Bieganowska; Linda Middleton; Francesco Morandi; Giancarlo Ottonello Journal: Orphanet J Rare Dis Date: 2014-12-05 Impact factor: 4.123
Authors: Ha Trang; Martin Samuels; Isabella Ceccherini; Matthias Frerick; Maria Angeles Garcia-Teresa; Jochen Peters; Johannes Schoeber; Marek Migdal; Agneta Markstrom; Giancarlo Ottonello; Raffaele Piumelli; Maria Helena Estevao; Irena Senecic-Cala; Barbara Gnidovec-Strazisar; Andreas Pfleger; Raquel Porto-Abal; Miriam Katz-Salamon Journal: Orphanet J Rare Dis Date: 2020-09-21 Impact factor: 4.123